I received an email from my ICAP associate, Christina England today. Her message explained a mystery I have been trying to solve for the past week. My site stats have indicated a large number of hits from Russian ISPs and those visitors spending time investigating my article archive. Christina noted the same site visitor anomalies and traced the traffic back to http://www.oodvrs.ru/article/index.php?id_page=47&id_article=940 and found her article about ICAP communications with the German Scientists of RKI concerning the safety of the HPV vaccines Gardasil and Cervarix. This article tracks back to our papers. It is amazing but our message has been have been translated into Russian. The word is getting out there yippee! Congrats to Christina!

A study, published in Tuesday’s issue of The Lancet, said that as well as protecting against the two most common virus types, the GlaxoSmithKline Plc’s Cervarix vaccine also provides protection against the next three most common cancer-causing virus types. GlaxoSmithKline Plc’s is Europe’s biggest drug company.

The study was conducted in Australia, in 2007 and reported in The British Medical Journal in Dec 2008. Sharon Choo of the Royal Children’s Hospital in Melbourne reported that during 2007 more than 380,000 doses of the vaccine had been administered in schools in Victoria and South Australia under the Australian immunization program. Choo and colleagues noted some components of Merck’s treatment — such as aluminum salts and yeast — have been associated with allergic reactions. In the British Medical Journal article, published in late 2008, she and her colleges are quoted as saying, “Our clinical recommendation is that females with suspected hypersensitivity to the quadrivalent vaccine should be evaluated before receiving more doses, and any challenges with the same vaccine should be carried out in a supervised setting.”

International Coalition of Advocates for the People’s first educational advocacy effort has been a success. Seven women who became international advocates wrote a paper about HPV vaccines to educate all necessary parties in Europe. This paper has been distributed throughout Europe and to select individuals in the United States. Presently, thirteen German scientists from the Robert Koch Institute are questioning the effectiveness of these vaccines. They are also asking for evidence now from the Standing Committee based on the scientists’ views.

All any of us, who have raised questions about the rapid deployment of the HPV vaccines, Gadasil and Cervarix, have ever wanted, is an objective review of the clinic trial information by scientist not related to Big Pharma. In Germany, the Robert Koch Institute is in that process right now. The question American, Canadian, and other EU citizens are asking is, “Why are our own governmental agencies and regulators so against a similar objective review of the clinic trial information and independent medical review of the thousands of reported HPV-vaccine adverse effect cases? Is the no “Robert Koch Institute-like” organization that can ask the questions for our citizens?”